Validation data for Anti-hCD70-hIgG1NQ

https://www.invivogen.com/anti-hcd70-mabs

For research use only

Version 23H22-AK

Anti-hCD70-hIgG1NQ is a recombinant monoclonal antibody (mAb) featuring a variable region of vorsetuzumab, targeting the human CD70 and the non-glycosolyated constant region of the enigneered human IgG1 isotype (hIgG1NQ).CD70 is an important immune checkpoint in the activation of T cells, however it can be expressed and hijacked by tumor cells to evade the immune response. The detection of hCD70 by Anti-hCD70-hIgG1NQ has been verified by flow cytometry using EL4 cells transfected wth hCD70 **(Figure 1)**. The induction of ADCC has been validated using InvivoGen's Raji-Null and Jurkat-Lucia™ NFAT-CD16 reporter cells **(Figure 2)**.

Binding of Anti-hCD70-hIgG1NQ mAb to hCD70



Figure 1. Binding of Anti-hCD70-hIgG1NQ mAb to hCD70. EL4 wildtype (WT) and EL4-hCD70 cells were incubated for 30 minutes with 250 ng of Anti-hCD70-hIgG1NQ. Subsequently, a secondary PE-labeled antibody was added and incubated at room temperature for 30 minutes. The binding affinity was assessed using flow cytometry.

Comparison of ADCC induction of Anti-hCD70 mAbs



Figure 2. Comparison of ADCC potency for native and engineered anti-human CD70 antibody isotypes. Raji-Null cells were incubated with gradient concentrations of Anti-hCD70 or Anti-β-galactosidase (β-gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with target Raji-Null cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™ 4 Lucia/Gaussia. Percentages of the maximal response normalized to the IgG1 isotype are shown.

TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3-622-34-80
E-mail: info@invivogen.com

InvivoGen
www.invivogen.com